SCHEMBL6192555

SCHEMBL6192555

C(#Cc1ccc2ccc(Cc3ccccc3)cc2c1)Cc1ccc2occc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.41
HTR1B P28222 4/20 0.39
ASIC3 Q9UHC3 1/20 0.38
IDO1 P14902 1/20 0.36
CTNNB1 P35222 2/20 0.35
WNT3A P56704 2/20 0.35
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
GRM5 P41594 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
GPR52 Q9Y2T5 1/20 0.32
CHRNA1 P02708 2/20 0.31
CHRNG P07510 2/20 0.31
CHRNB1 P11230 2/20 0.31
CHRNB2 P17787 2/20 0.31
CHRNB4 P30926 2/20 0.31
CHRNA3 P32297 2/20 0.31
CHRNA7 P36544 2/20 0.31
CHRNA4 P43681 2/20 0.31
HTR3A P46098 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6214520 0.96 CYP2A6 (0.42) CYP2A6HTR1BASIC3IDO1CTNNB1
SCHEMBL6192542 0.84 ASIC3 (0.47) CYP2A6ASIC3FFAR1FFAR4
SCHEMBL6214143 0.83 ALOX5 (0.38) CYP2A6HTR1BASIC3IDO1CTNNB1
SCHEMBL6194288 0.81 ASIC3 (0.39) ASIC3FFAR1FFAR4
SCHEMBL1602111 0.81 HTR1B (0.53) CYP2A6HTR1BIDO1CTNNB1WNT3A
SCHEMBL6194302 0.81
SCHEMBL6214149 0.80 CYP2A6 (0.35) CYP2A6HTR1BASIC3IDO1CTNNB1
SCHEMBL6193988 0.80 HTR2B (0.40) ASIC3FFAR1FFAR4
SCHEMBL6210633 0.80 ABCB1 (0.35) CYP2A6HTR1BIDO1CTNNB1WNT3A
SCHEMBL6843302 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539163-A1 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-06-15 EP disclosed
US-20040043983-A1 Naphthalene derivatives as matrix metalloproteinase inhibitors LI JIE JACK (US) 2004-03-04 US disclosed
WO-2004014377-A1 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043983-A1 Naphthalene derivatives as matrix metalloproteinase inhibitors MMP9, MMP8, MMP13 CYP2A6 631/4885HTR1B 4458/4885ASIC3 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.